8-K: Sera Prognostics' PRIME Study Shows Significant Reduction in Preterm Birth Complications

Sera Prognostics' PRIME study demonstrates a significant reduction in neonatal morbidity and hospital stays using the PreTRM test and targeted interventions.

Summary

• Sera Prognostics announced positive results from its PRIME study, a multicenter randomized clinical trial involving 5,018 pregnant women.
• The study evaluated the effectiveness of the PreTRM test, which identifies women at higher risk of preterm birth, combined with interventions like progesterone, low-dose aspirin, and nurse phone calls.
• The PRIME study met its co-primary endpoints, showing a 25% reduction in neonatal morbidity and mortality and an 18% reduction in neonatal length of hospital stay in the modified Intent to Treat (mITT) population.
• Using the Full Analysis Set (FAS), the study showed a 20% reduction in neonatal morbidity and a 22% reduction in NICU admissions.
• The Intent to Treat (ITT) analysis showed a 20% reduction in neonatal morbidity and an 8% reduction in neonatal length of hospital stay, as well as a 20% reduction in NICU admissions and a 6% reduction in NICU length of stay.
• A meta-analysis of the PRIME and AVERT studies showed a pooled mITT effect of a 22% reduction in both neonatal morbidity and neonatal length of stay.
• The number needed to screen (NNS) to reduce a NICU day is estimated to be 3 to 4.
• Sera Prognostics estimates its cash, cash equivalents, and marketable securities to be approximately $68.2 million as of December 31, 2024.

Sentiment

Score: 9

Explanation: The document presents very positive results from the PRIME study, with significant reductions in key metrics related to preterm birth. The company also has a strong cash position, which supports a positive outlook.

Positives

• The PRIME study successfully met its co-primary endpoints, demonstrating the effectiveness of the PreTRM test and interventions.
• The study showed significant reductions in neonatal morbidity, mortality, and hospital stays across multiple analysis populations.
• The meta-analysis of PRIME and AVERT studies further validates the positive impact of the PreTRM test.
• The low number needed to screen (3-4) to reduce a NICU day highlights the potential cost-effectiveness of the PreTRM test.
• The company has a strong cash position of approximately $68.2 million, which is expected to support commercialization efforts.

Negatives

• The estimated cash balance of $68.2 million is unaudited and preliminary, and may change.
• The company acknowledges that the effect size was diluted in the ITT analysis due to the inclusion of healthy babies with short hospital stays.
• The company's future success depends on broad scientific and market acceptance of the PreTRM test.

Risks

• The company faces risks related to the need for broad scientific and market acceptance of the PreTRM test.
• There is a risk of competition from other companies in the same space.
• The company's success depends on the availability of critical suppliers.
• The company's success depends on potential third-party payer coverage and reimbursement.
• Changes in U.S. Food and Drug Administration regulation of laboratory-developed tests could impact the company.
• The company's intellectual property rights protecting its tests and market position are also a risk.

Future Outlook

The company anticipates that the PreTRM test has the potential to address a significant unmet need in preterm birth prediction and prevention, and plans to continue commercialization efforts.

Management Comments

• The company believes that the PRIME study results show that the use of its PreTRM Test, combined with preventive interventions, have the potential to address a significant unmet need.
• The company believes the foregoing validates the use of its PreTRM Test to implement a screen and treat strategy among low-risk patients to meaningfully reduce adverse neonatal clinical outcomes and provide significant savings in cost of care.

Industry Context

The announcement is significant as preterm birth is a major clinical and economic challenge, and the PRIME study results suggest that the PreTRM test could be a valuable tool in addressing this issue. The results are consistent with the company's prior AVERT study, further validating the technology.

Comparison to Industry Standards

• The PRIME study results are compared to the AVERT study, showing consistent reductions in neonatal morbidity and length of stay.
• The number needed to screen (NNS) of 3-4 to reduce a NICU day is a key metric, and is compared to other widely adopted tests such as transvaginal ultrasound cervical length plus progesterone which has a NNS of 150 to prevent 1 NICU admission and 41 to prevent 2 NICU admissions.
• The company references ACOG guidelines and practice bulletins, indicating an awareness of industry standards and the need for clinical acceptance.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results and the company's solid financial position.
• Healthcare providers may be more inclined to adopt the PreTRM test based on the study's findings.
• Patients may benefit from reduced risks of preterm birth complications and shorter hospital stays.
• Payers may see potential cost savings from reduced NICU admissions and length of stay.

Next Steps

• The company plans to continue commercialization efforts for the PreTRM test.
• The company will present the PRIME study results at a virtual R&D day session.
• The company will include complete annual results in its Annual Report on Form 10-K for the year ended December 31, 2024.

Key Dates

Keywords

Preterm Birth, PreTRM Test, Neonatal Morbidity, Neonatal Mortality, NICU, Maternal Health, Biomarker, Progesterone, Aspirin, Healthcare Costs